Loading…
Leukotriene receptor antagonists in the treatment of allergic rhinitis
OBJECTIVE: To review the literature examining the clinical use of leukotriene receptor antagonists in the treatment of allergic rhinitis. DATA SOURCES: Biomedical literature accessed through MEDLINE (1990–November 2000) and Current Contents (week 35 of 1999 to week 48 of 2000). Key terms included le...
Saved in:
| Published in: | The Annals of pharmacotherapy 2001-10, Vol.35 (10), p.1274-1277 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c374t-bbb1491ed0a1fcbeb9561f8c2e15b4232c7aac2ae201cb3325507be812ececef3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c374t-bbb1491ed0a1fcbeb9561f8c2e15b4232c7aac2ae201cb3325507be812ececef3 |
| container_end_page | 1277 |
| container_issue | 10 |
| container_start_page | 1274 |
| container_title | The Annals of pharmacotherapy |
| container_volume | 35 |
| creator | Maynard, ML Ernst, ME |
| description | OBJECTIVE:
To review the literature examining the clinical use of leukotriene receptor antagonists in the treatment of allergic rhinitis.
DATA SOURCES:
Biomedical literature accessed through MEDLINE (1990–November 2000) and Current Contents (week 35 of 1999 to week 48 of 2000). Key terms included leukotriene antagonists, montelukast, zafirlukast, and rhinitis (allergic).
DATA SYNTHESIS:
Preliminary evidence on the clinical use of either montelukast or zafirlukast as monotherapy is equivocal, with one study noting benefit and another noting lack of benefit in symptom amelioration. A third study suggests that these agents may have a role in further modifying allergic rhinitis symptoms when used in combination with standard treatments.
CONCLUSIONS:
Future large-scale studies should assess the efficacy of these agents in the treatment of allergic rhinitis, in particular, to identify subsets of patients likely to derive the most benefit. Available data suggest it is reasonable and safe to add these agents to standard therapy if symptomatology remains unresolved. |
| doi_str_mv | 10.1345/aph.1A001 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72225956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1A001</sage_id><sourcerecordid>72225956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-bbb1491ed0a1fcbeb9561f8c2e15b4232c7aac2ae201cb3325507be812ececef3</originalsourceid><addsrcrecordid>eNptkD1PwzAQhi0E4qMw8AdQFkAMKT47bpKxQnxJlVhgtmxzaQyJU2xHFf8eQyt1Ybobnnvf00PIOdAp8ELcqlU7hTmlsEeOQRQsn7GS7qedzmhOWUWPyEkIH5TSGlh9SI4AZqWoRH1MHhY4fg7RW3SYeTS4ioPPlItqOTgbYsisy2KLWfSoYo8uZkOTqa5Dv7Qm8611NtpwSg4a1QU8284JeXu4f717yhcvj89380VueFnEXGsNRQ34ThU0RqOuxQyayjAEoQvGmSmVMkwho2A050wIWmqsgKXPDDZ8Qq42uSs_fI0YouxtMNh1yuEwBlkyxkQKTeDNBjR-CMFjI1fe9sp_S6DyV5pM0uSftMRebENH3eP7jtxaSsDlFlDBqK7xyhkbdlxBS17VsPsuqCXKj2H0Lsn4t_F6A7Z22a6tRxn65DT1g1yv11z83bCy4D-0to-N</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72225956</pqid></control><display><type>article</type><title>Leukotriene receptor antagonists in the treatment of allergic rhinitis</title><source>SAGE</source><creator>Maynard, ML ; Ernst, ME</creator><creatorcontrib>Maynard, ML ; Ernst, ME</creatorcontrib><description>OBJECTIVE:
To review the literature examining the clinical use of leukotriene receptor antagonists in the treatment of allergic rhinitis.
DATA SOURCES:
Biomedical literature accessed through MEDLINE (1990–November 2000) and Current Contents (week 35 of 1999 to week 48 of 2000). Key terms included leukotriene antagonists, montelukast, zafirlukast, and rhinitis (allergic).
DATA SYNTHESIS:
Preliminary evidence on the clinical use of either montelukast or zafirlukast as monotherapy is equivocal, with one study noting benefit and another noting lack of benefit in symptom amelioration. A third study suggests that these agents may have a role in further modifying allergic rhinitis symptoms when used in combination with standard treatments.
CONCLUSIONS:
Future large-scale studies should assess the efficacy of these agents in the treatment of allergic rhinitis, in particular, to identify subsets of patients likely to derive the most benefit. Available data suggest it is reasonable and safe to add these agents to standard therapy if symptomatology remains unresolved.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1A001</identifier><identifier>PMID: 11675859</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Cincinnati, OH: Harvey Whitney Books</publisher><subject>Acetates - therapeutic use ; Adolescent ; Adult ; Aged ; Biological and medical sciences ; Histamine and antagonists. Allergy ; Humans ; Leukotriene Antagonists - therapeutic use ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Quinolines - therapeutic use ; Randomized Controlled Trials as Topic ; Rhinitis, Allergic, Perennial - drug therapy ; Rhinitis, Allergic, Perennial - epidemiology ; Tosyl Compounds - therapeutic use ; United States - epidemiology</subject><ispartof>The Annals of pharmacotherapy, 2001-10, Vol.35 (10), p.1274-1277</ispartof><rights>2001 SAGE Publications</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-bbb1491ed0a1fcbeb9561f8c2e15b4232c7aac2ae201cb3325507be812ececef3</citedby><cites>FETCH-LOGICAL-c374t-bbb1491ed0a1fcbeb9561f8c2e15b4232c7aac2ae201cb3325507be812ececef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14073891$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11675859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maynard, ML</creatorcontrib><creatorcontrib>Ernst, ME</creatorcontrib><title>Leukotriene receptor antagonists in the treatment of allergic rhinitis</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>OBJECTIVE:
To review the literature examining the clinical use of leukotriene receptor antagonists in the treatment of allergic rhinitis.
DATA SOURCES:
Biomedical literature accessed through MEDLINE (1990–November 2000) and Current Contents (week 35 of 1999 to week 48 of 2000). Key terms included leukotriene antagonists, montelukast, zafirlukast, and rhinitis (allergic).
DATA SYNTHESIS:
Preliminary evidence on the clinical use of either montelukast or zafirlukast as monotherapy is equivocal, with one study noting benefit and another noting lack of benefit in symptom amelioration. A third study suggests that these agents may have a role in further modifying allergic rhinitis symptoms when used in combination with standard treatments.
CONCLUSIONS:
Future large-scale studies should assess the efficacy of these agents in the treatment of allergic rhinitis, in particular, to identify subsets of patients likely to derive the most benefit. Available data suggest it is reasonable and safe to add these agents to standard therapy if symptomatology remains unresolved.</description><subject>Acetates - therapeutic use</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Histamine and antagonists. Allergy</subject><subject>Humans</subject><subject>Leukotriene Antagonists - therapeutic use</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinolines - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Rhinitis, Allergic, Perennial - drug therapy</subject><subject>Rhinitis, Allergic, Perennial - epidemiology</subject><subject>Tosyl Compounds - therapeutic use</subject><subject>United States - epidemiology</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNptkD1PwzAQhi0E4qMw8AdQFkAMKT47bpKxQnxJlVhgtmxzaQyJU2xHFf8eQyt1Ybobnnvf00PIOdAp8ELcqlU7hTmlsEeOQRQsn7GS7qedzmhOWUWPyEkIH5TSGlh9SI4AZqWoRH1MHhY4fg7RW3SYeTS4ioPPlItqOTgbYsisy2KLWfSoYo8uZkOTqa5Dv7Qm8611NtpwSg4a1QU8284JeXu4f717yhcvj89380VueFnEXGsNRQ34ThU0RqOuxQyayjAEoQvGmSmVMkwho2A050wIWmqsgKXPDDZ8Qq42uSs_fI0YouxtMNh1yuEwBlkyxkQKTeDNBjR-CMFjI1fe9sp_S6DyV5pM0uSftMRebENH3eP7jtxaSsDlFlDBqK7xyhkbdlxBS17VsPsuqCXKj2H0Lsn4t_F6A7Z22a6tRxn65DT1g1yv11z83bCy4D-0to-N</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>Maynard, ML</creator><creator>Ernst, ME</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011001</creationdate><title>Leukotriene receptor antagonists in the treatment of allergic rhinitis</title><author>Maynard, ML ; Ernst, ME</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-bbb1491ed0a1fcbeb9561f8c2e15b4232c7aac2ae201cb3325507be812ececef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acetates - therapeutic use</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Histamine and antagonists. Allergy</topic><topic>Humans</topic><topic>Leukotriene Antagonists - therapeutic use</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinolines - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Rhinitis, Allergic, Perennial - drug therapy</topic><topic>Rhinitis, Allergic, Perennial - epidemiology</topic><topic>Tosyl Compounds - therapeutic use</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maynard, ML</creatorcontrib><creatorcontrib>Ernst, ME</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maynard, ML</au><au>Ernst, ME</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Leukotriene receptor antagonists in the treatment of allergic rhinitis</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>35</volume><issue>10</issue><spage>1274</spage><epage>1277</epage><pages>1274-1277</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>OBJECTIVE:
To review the literature examining the clinical use of leukotriene receptor antagonists in the treatment of allergic rhinitis.
DATA SOURCES:
Biomedical literature accessed through MEDLINE (1990–November 2000) and Current Contents (week 35 of 1999 to week 48 of 2000). Key terms included leukotriene antagonists, montelukast, zafirlukast, and rhinitis (allergic).
DATA SYNTHESIS:
Preliminary evidence on the clinical use of either montelukast or zafirlukast as monotherapy is equivocal, with one study noting benefit and another noting lack of benefit in symptom amelioration. A third study suggests that these agents may have a role in further modifying allergic rhinitis symptoms when used in combination with standard treatments.
CONCLUSIONS:
Future large-scale studies should assess the efficacy of these agents in the treatment of allergic rhinitis, in particular, to identify subsets of patients likely to derive the most benefit. Available data suggest it is reasonable and safe to add these agents to standard therapy if symptomatology remains unresolved.</abstract><cop>Cincinnati, OH</cop><pub>Harvey Whitney Books</pub><pmid>11675859</pmid><doi>10.1345/aph.1A001</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1060-0280 |
| ispartof | The Annals of pharmacotherapy, 2001-10, Vol.35 (10), p.1274-1277 |
| issn | 1060-0280 1542-6270 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72225956 |
| source | SAGE |
| subjects | Acetates - therapeutic use Adolescent Adult Aged Biological and medical sciences Histamine and antagonists. Allergy Humans Leukotriene Antagonists - therapeutic use Medical sciences Middle Aged Pharmacology. Drug treatments Quinolines - therapeutic use Randomized Controlled Trials as Topic Rhinitis, Allergic, Perennial - drug therapy Rhinitis, Allergic, Perennial - epidemiology Tosyl Compounds - therapeutic use United States - epidemiology |
| title | Leukotriene receptor antagonists in the treatment of allergic rhinitis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T13%3A05%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Leukotriene%20receptor%20antagonists%20in%20the%20treatment%20of%20allergic%20rhinitis&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Maynard,%20ML&rft.date=2001-10-01&rft.volume=35&rft.issue=10&rft.spage=1274&rft.epage=1277&rft.pages=1274-1277&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1A001&rft_dat=%3Cproquest_cross%3E72225956%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c374t-bbb1491ed0a1fcbeb9561f8c2e15b4232c7aac2ae201cb3325507be812ececef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72225956&rft_id=info:pmid/11675859&rft_sage_id=10.1345_aph.1A001&rfr_iscdi=true |